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ABSTRACT 
Restoration of the protein dystrophin on muscle membrane is the goal of many research lines aimed 
at curing Duchenne muscular dystrophy (DMD). Ongoing pre-clinical and clinical trials suggest that 
partial restoration of dystrophin might be sufficient to significantly reduce muscle damage.  Different 
myogenic progenitors are candidates for the cell therapy of muscular dystrophies but only satellite 
cells and pericytes have already entered clinical experimentation.  
Our study aims at providing in vitro quantitative evidence of the ability of mesoangioblasts to restore 
dystrophin, in terms of protein accumulation and distribution, within myotubes derived from DMD 
patients using a micro-engineered model.  
We designed an ad hoc experimental strategy, seeking to miniaturizing on chip the standard process 
of muscle regeneration, independently from variables such as inflammation and fibrosis. It is based 
on the co-culture, at different ratios, of human dystrophin positive myogenic progenitors and 
dystrophin negative myoblasts in a substrate with muscle-like physiological stiffness and cell 
micropatterns. Results showed that both healthy myoblasts and mesoangioblasts restore dystrophin 
expression in DMD myotubes. However, mesoangioblasts showed unexpected efficiency with respect 
to myoblasts in dystrophin production in terms of amount of protein produced (40% vs 15%) and 
length of the dystrophin membrane domain (210-240µm vs 40-70µm). 
These results show that our microscaled in vitro model of human DMD skeletal muscle validate 
previous in vivo pre-clinical work and may be used to predict efficacy of new methods aimed at 
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enhancing dystrophin accumulation and distribution before they are tested in vivo, reducing time, 
costs and variability of clinical experimentation.  
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1. Introduction 
Duchenne muscular dystrophy (DMD) is a genetic disease caused by mutations in the gene encoding 
the protein dystrophin1. Dystrophin is a critical component of the dystrophin-glycoprotein complex 
(DGC) in muscle that links the actin cytoskeleton to the extracellular matrix of myofibers. The lack 
of a functional dystrophin protein causes loss of proper localization of many of the DGC components 
at the sarcolemma of muscle fibers leading to membrane instability and myofiber degeneration2. 
DMD primarily affects skeletal muscles and results in progressive paralysis and premature death. At 
the moment, no successful treatments are available, but new drug, gene and cell therapy strategies are 
under clinical investigation3,4. 
Many of the therapeutic strategies and research lines for DMD are focused on the restoration of the 
protein dystrophin. Recently completed clinical trials showed that 15%5 and 18%6 of normal levels 
of dystrophin resulted in a moderate but significant clinical benefit during a 12 weeks study.  Indeed 
reports indicate that dystrophin production as low as 30% of that found in healthy animals or 
individuals prevents muscular XLDC dystrophy in humans7,8.  
In this scenario, cell therapy has good potential. In particular, strategies able to restore the 
compartment of muscle stem cells are amongst the most promising, since they would not require 
continuous injections to sustain the muscle regeneration. However, cell therapy is a complex 
regenerative process which includes intra-arterial (or intramuscular) cell delivery, crossing the blood 
vessel wall, survival, migration and contribution to skeletal muscle regeneration by fusion with 
regenerating muscle fibers and by entering the satellite cell compartment8,9. In this perspective, 
pericytes are a promising cell source because of their peculiar characteristics: these cells surround the 
endothelium of small vessels and can differentiate into different mesoderm cell types, including 
skeletal muscle8,10. When delivered into the arterial circulation, mouse mesoangioblasts cross the 
blood vessel wall and participate in skeletal muscle regeneration, ameliorating signs of muscular 
dystrophy in animal models such as the α-sarcoglycan–null (Sgca-null)11 and mdx8 mice and the 
golden retriever muscular dystrophy (GRMD) dog12. When cells similar to mouse mesoangioblasts 
were isolated from human adult skeletal muscle they were shown to correspond to a subset of 
pericytes, expressing alkaline phosphatase13. Cells derived from in vitro expansion of human skeletal 
muscle vasculature pericytes, which we deemed mesoangioblasts, have recently been transplanted in 
DMD patients in a phase I/IIa clinical trial (EudraCT no. 2011-000176-33) whose results showed 
safety and limited efficacy14.  
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Clinical trials are expensive and time-consuming processes required before drugs and therapies reach 
the market and the clinics: many drugs are withdrawn and many therapies fail during clinical trials. 
Moreover it may be extremely useful to test a large number of variables that may synergise to increase 
efficacy (e.g. combination of different drugs with cell/gene therapy) but it is in fact almost impossible 
because of logistic and economical reasons. In order to overcome this problem, the concept of 
“clinical trial on dish” or “clinical trial on chip” has been recently proposed15. Such complementary 
approaches could provide therapy efficiency information at early stage of protocol development. For 
instance, Liang and colleagues validate the capacity of a library of human induced pluripotent stem 
cell–derived cardiomyocytes to be used as a clinical trial in a dish model for accurate detection of 
patient-specific drug responses and drug-induced cardiotoxicity profiles16. The concept of “clinical 
trial on chip” is based on the advances in micro-technology, microfluidics and development of 
physiologically relevant 3D organs or tissues at the microscale. The attempt is to give a cheaper, 
faster and more accurate way to screen drugs or therapies for efficacy and toxicity. For a review of 
the potential of this approach see15,17–19. 
So far no study reports the use of skeletal muscle for clinical evaluation of therapy in a dish. However, 
the derivation of physiologically relevant skeletal muscle tissues in vitro is not straightforward. 
Physiological stimuli and interactions must be reproduced and finely controlled. In particular, the 
development of skeletal muscle model and a DMD assay requires the formation of a mature tissue 
with a high degree of differentiation and a proper expression of dystrophin, which is a late marker, 
not commonly detected in standard in vitro cultures. For this reason, primary myoblasts freshly 
isolated from patient should be used, since they can be expanded and successfully differentiated into 
mature myotubes, the functional unit of skeletal muscle. The major drawback of this cell source, the 
relatively low number of derived cells, could be overcome with the design of micro-scaled assay able 
to maintain physiological relevance.  
In this scenario, we developed a human-based skeletal muscle tissue-on-chip derived from healthy 
and DMD donors 20,21. We engineered the culture substrate, in terms of mechanical and topological 
properties, for optimizing human myoblasts differentiation and obtaining the expression of dystrophin 
in vitro20.  
In this work, we aim at exploiting the developed human-based skeletal muscle tissue-on-chip for 
testing a number of experimental variables which may subsequently benefit the design of a protocol 
for future clinical trials, leading in the end to more efficacious stem cell therapies. In this specific 
work we tested the ability of human mesoangioblasts, in comparison with human myoblasts, to restore 
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level of dystrophin expression and distribution along the myotube when co-cultured with myoblasts 
from DMD patients, using a micro-engineered DMD model of skeletal muscle. Wild-type 
(dystrophin-positive, Dys+) cells were co-cultured with DMD cells (dystrophin-negative, Dys-) at 
different ratios. The co-culture of Dys+ with Dys- cells induced the formation of myotubes containing 
nuclei encoding for dystrophin and DMD nuclei not encoding for this protein. 
It is worth to underline that the mesoangioblasts used in this study were harvested from three healthy 
donors, who participated to a phase I/II clinical trial (EudraCT no. 2011-000176-33).  
 
 
2. Materials and Methods 
2.1 Cell Culture. 
Throughout the manuscript we refer to myoblasts (Mbs) as the in vitro counterpart of satellite cell-
derived myoblasts. We refer to mesoangioblasts (Mabs) as an in vitro expanded peri-vascular cell 
population sharing markers of skeletal muscle pericytes and likely corresponsing to a subpupolation 
thereof. Mesoangioblasts isolated from post-natal mammalian muscle express (>95%) markers 
common to MSC such as CD44, CD90, CD13 etc. but not endothelial or hematopoietic markers such 
as CD31, CD34 and CD45. They do not express the satellite cell marker CD56. As for “pericyte” 
markers they express, at variable extent in different preparations, PDGF Receptor beta, smooth alpha 
actin, NG2, Alkaline Phosphatase and CD14622. 
  
Human primary myoblasts were provided by the ‘‘Telethon BioBank’’ (Telethon Research Service, 
Istituto Nazionale Neurologico ‘‘Carlo Besta’’, Milano, Italy). They are derived from healthy donors 
(Dys+) and from DMD affected donors (Dys-). The mutation of DMD donor is the deletion of Exon 
45. Myoblasts were expanded with proliferation medium: 60% High-Glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM Glutamax, Gibco-Invitrogen, Waltham, Massachusetts), 20% Medium 
M199 (Sigma-Aldrich, St. Louis, Missouri), 20% fetal bovine serum (FBS, Gibco-Invitrogen, 
Waltham, Massachusetts), 10 ng/mL EGF (PeproTech, Rocky Hill, New Jersey), 2 ng/mL β-FGF 
(PeproTech, Rocky Hill, New Jersey), 10 µg/mL insulin (insulin from bovine pancreas, Sigma-
Aldrich, St. Louis, Missouri) and 1% penicillin−streptomycin−glutamine mix solution (Gibco-
Invitrogen, Waltham, Massachusetts); on standard 100 mm tissue culture Petri dishes previously 
coated with 0.5% gelatin solution (gelatin from porcine skin, Sigma-Aldrich, St. Louis, Missouri).  
Human mesoangioblasts were derived from skeletal muscle biopsies of healthy subjects as 
described22.  Biopsies were obtained from the Orthopedic Surgery Department of the San Raffaele 
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Hospital following authorization of the Institute Ethics Committee and signature of an informed 
consent by the patient or his/her parents/caregivers.			
Briefly the biopsy was cleaned from fat and connective tissue, minced in small fragments that were 
plated on collagen coated dishes (6 or 9 cm depending on the size) and cultured with 1 or 2 ml 
(respectively) of Megacell medium (see below). More medium is gently added the next day. After a 
week, when cells have outgrown form the explant, loosely attached or floating cells are collected by 
gentle pipetting and sub-cultured as P1.  
Human mesoangioblasts derived from healthy donors (Dys+) were expanded in gelatin-coated dish 
with proliferation medium composed of MegaCell™ DMEM (Sigma-Aldrich, St. Louis, Missouri) 
supplemented with 5% heat inactivated fetal bovine serum (Gibco-Invitrogen, Waltham, 
Massachusetts), 2 mM L-Glutamine (Gibco-Invitrogen, Waltham, Massachusetts), 1% non-essential 
aminoacids (Gibco-Invitrogen, Waltham, Massachusetts), 0,1 mM β-mercaptoethanol (Gibco-
Invitrogen, Waltham, Massachusetts), 5 ng/ml β-FGF (PeproTech, Rocky Hill, New Jersey), 1% 
penicilin-streptomicin (Gibco-Invitrogen, Waltham, Massachusetts). Mesoangioblasts were induced 
to differentiate into myotubes by changing proliferation medium with the same differentiating 
medium used for human primary myoblasts. Human primary myoblasts and mesoangioblasts were 
induced to form myotubes in differentiating medium: 98% DMEM Glutamax (Gibco-Invitrogen, 
Waltham, Massachusetts), 2% horse serum (Gibco-Invitrogen, Waltham, Massachusetts), 30 µg/mL 
insulin and 1% penicillin−streptomycin−glutamine mix solution (Gibco-Invitrogen, Waltham, 
Massachusetts).  We used three batches of mesoangioblasts, three batches of myoblast from healthy 
individuals and one batch of myoblast from DMD patients.  
2.2 Dys+ and Dys- co-culture on micro-patterned substrate 
The engineered culture system was prepared as previously described20,21. Briefly, hydrogel with 
muscle-like stiffness were fabricated with acrylamide/bisacrylamide 29:1 40% solution (Sigma-
Aldrich, St. Louis, Missouri) over a 25mm coverslip glass. The pre-polymer was diluted in phosphate 
buffered saline (PBS, Sigma-Aldrich, St. Louis, Missouri) to the final concentrations of 10%. The 
photoinitiator (Irgacure 2959; Ciba Specialty Chemicals, Basel, Switzerland) was added to the 
acrylamide/bis-acrylamide solution with a final concentration of 20 mg/ml, and mixed thoroughly. 
Hydrogel polymerization occurred by exposing the prepolymer solution to UV light for 3 min (high-
pressure mercury vapor lamp (Philips HPR 125 W) emitting at 365 nm with an incident light intensity 
of 20 mW/cm2). Non-polymerized acrylamide was removed using distilled water. Hydrogel films 
were immersed in ultra-pure distilled water for 48 h to ensure complete removal of the unreacted 
monomeric units or photoinitiator and final sterilization occurred after 20 min exposure to UV light 
under a sterile hood. The hydrogel has a diameter of 18 mm. 
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Matrigel (2.5% v/v in DMEM) was used for the micropattern. Micropatterning geometry (parallel 
lanes, 1 cm2) was optimized for myoblasts and pericytes, according to our previous work21. Dys+ and 
Dys- cells were co-cultured with the following ratio: 1:1, 1:2 and 1:9, respectively. 300 µL of the cell 
suspension (1×105 cells/mL) were dropped over the micropatterned hydrogel and the cultures kept at 
37 °C, 5% CO2. Co-cultures were maintained in a 1:1 mix of each specific proliferation medium for 
1 or 2 days, followed by 8 days of culture in differentiating medium. 
2.3 Western Blot 
The cultures were treated ice-cold with 50 µl of lysis buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
0.5 mM DTT, 10% Glycerol, 1 mM EDTA, 10 mM MgCl2, 2% SDS, 1% Triton X-100 1 mM PMSF, 
1 mM NaV, 5 mM NaF, 3 mM β-glycerol (all Sigma, St. Louis, Missouri), and Complete EDTA-free 
protease inhibitor cocktail (Roche, Basel, Switzerland). Lysis buffer were dropped directly onto the 
hydrogel surfaces and incubated at 4°C for 1 h. After 1 h treatment, lysis buffer was resuspended on 
the hydrogel in order to collect all the cellular contents. Cell fractions were sedimented by 
centrifugation at 13000 g for 20 min at 4°C, and supernatant collected. 10 µg per lane of protein 
extract were solubilized in loading buffer (Gibco-Invitrogen, Waltham, Massachusetts), 10% DTT 
(Gibco-Invitrogen, Waltham, Massachusetts) and heated for 10 minutes at 70°C. Proteins were 
resolved in 3-8% precast gels (Tris-Acetate NuPAGE, Gibco-Invitrogen, Waltham, Massachusetts) 
and then transferred on PVDF membranes (Gibco-Invitrogen, Waltham, Massachusetts) under a 
potential difference of 45V, 400mA for 6 h. Membranes were blocked with 5% nonfat dry milk (Bio-
Rad, Hercules, California) in TBST (TBS, 0.05% Tween 20) and then probed with primary antibodies 
for dystrophin (Abcam, Cambridge, UK), myosin heavy chain II (Sigma-Aldrich, St. Louis, Missouri) 
and β-actin (Sigma-Aldrich, St. Louis, Missouri), and then with the proper HRP–conjugated 
secondary antibodies: goat anti-rabbit antibody (Gibco-Invitrogen, Waltham, Massachusetts) and 
goat anti-mouse antibody (BioRad, Hercules, California). Proteins were visualized by enhanced 
chemiluminescence (Gibco-Invitrogen, Waltham, Massachusetts) and dystrophin content was 
quantified by densitometry using ImageJ software (US National Institutes of Health). For each culture 
condition, we quantified the intensity of dystrophin and myosin heavy chain bands and normalized 
them by the housekeeping protein, β-actin.  
2.4 Immunofluorescence 
Primary antibodies used in this study were against myosin heavy chain II (Sigma-Aldrich, St. Louis, 
Missouri) and dystrophin (Abcam, Cambridge, UK). A standard immunohistochemistry protocol was 
used20. Nuclei were counterstained with DAPI (Sigma Aldrich, St. Louis, Missouri) and samples were 
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mounted with Elvanol, and viewed under a fluorescence confocal microscope (Leica, Wetzlar, 
Germany). 
 
 
3. Results 
3.1 Assay validation  
The micro-engineered DMD model used in this study has been developed in our laboratory20,21 and 
it can be placed in a well of a standard 6 multiwell plate. It allows reducing the amount of reagents 
and the number of cells per sample: the culture surface is 0.5 cm2 and as few as 3 × 104 cells per 
sample can be used. In order to analyze the contribution of mesangioblasts derived from skeletal 
muscle vasculature and myoblasts in the restoration of dystrophin, we designed an experimental 
strategy based on the co-culture at different ratios of Dys+ and Dys- human cells in a micro-engineered 
in vitro model of human DMD skeletal muscle (Fig. 1). We named “Dys+ cells” either myoblasts or 
mesoangioblasts derived from skeletal muscle vasculature from healthy subjects; while “Dys- cells” 
refers to myoblasts harvested from DMD patients. 
We recently demonstrated that human myoblasts (both Dys+ and Dys-) differentiated optimally in our 
system and gave rise to fully differentiated myotubes20,21. Sarcomeric striations of myosin heavy 
chain (MyHC) are visible (Fig. 2A) and dystrophin is expressed and located at the membrane (Fig. 
2C). Also mesoangioblasts differentiate in our system: we obtained myotubes striated for MyHC (Fig. 
2B) with membrane localized dystrophin (Fig. 2D). As expected, myotubes derived from myoblasts 
of DMD patients show sarcomeric organization of MyHC (Fig. 2E) but no dystrophin expression 
(Fig. 2F). 
Since this study is based on the co-culture of human Dys- (myoblasts from DMD patients) and Dys+ 
myogenic cells (myoblasts and mesoangioblasts from healthy individuals), we developed an assay to 
distinguish the two cell populations.  
We tested a number of standard methodologies (Fig. 1S), but most failed for different reasons. The 
only methodology that allowed us to identify hybrid myotubes derived from fusion of Dys+ with Dys- 
cells is the use of lipophilic tracers. We marked Dys+ cells with Dil (red) and Dys- cells with DiO 
(green) and performed the co-culture experiments with two different ratio of cell from the two 
populations: 1 Dys+ cell every 9 Dys- cells (1:9) and 1 Dys+ cell every 29 Dys- cells (1:29) (Fig. 2G 
and 1S, D-F, n = 3 independent experiments).  
We observed four types of myotubes: myotubes formed only by Dys- cells, with a green fluorescence 
(Dys- myotubes); myotubes formed only by Dys+ cells, with a red fluorescence (Dys+ myotubes); 
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myotubes without fluorescence (Not marked myotubes), since these tracers marked around 80% of 
the cells; and myotubes formed by Dys+ and Dys- cells, with an orange fluorescence (Dys-/Dys+ 
myotubes). We quantified that Dys-/Dys+ myotubes represent the 51% and 42% (in 1:9 and 1:29 co-
culture, respectively) of myotubes expressing dystrophin (since Dys- myotubes do not express 
dystrophin). We thus concluded that the fusion of Dys- and Dys+ cells contribute to 50% of the 
dystrophin signal in the co-culture experiments. 
Unfortunately, tracking Dys- and Dys+ cell nuclei, which would help to provide better characterization 
of the systems, is not straightforward for long-term cell fusion experiments. Staining with Hoechst 
33258 22 (Fig 1S, A) resulted in a reduced cell viability after 5 days of culture. Human myoblasts 
infected with an adenovirus expressing the Green Fluorescent Protein (Fig 1S, B) showed low 
infection efficiency (around 50%). The use of a lentivirus encoding for a nuclear LacZ showed high 
efficiency (90%), however, the β-galactosidase was translocated to all the nuclei inside the myotube. 
After 10-12 days, we observed myotubes with all positive nuclei, myotubes with all negative nuclei 
and, in few cases, gradient of staining (Fig 1S, C). Thus, it was not possible to track clearly nuclei 
origin inside Dys- and Dys+ myotubes.  
The expression and accumulation of dystrophin (Dys) was then analyzed through western blot. First 
of all we verified that the culture of Dys+ cells performed in our micro-engineered model maintains 
the same ratio between dystrophin and MyHC of cultures performed in standard multiwell (48 wells) 
for both myoblasts and mesoangioblasts (Fig. 2H). The results showed that our micro-engineered 
model induces a differentiation consistent with standard culture substrate and increases the expression 
of dystrophin (Fig. 2H. n = 3 independent biological replicates). In addition, we determined the 
Dys/MyHC ratio in vivo (western blot of a biopsy of human muscle). The in vivo Dys/MyHC ratio is 
0.08, roughly 1/10 of the ratio found in myotubes formed in vitro (1.07 for mesoangioblasts and 0.97 
for myoblasts, on hydrogel) (data not shown). We expected this result because the average diameter 
of a myotube is 10 µm, while the diameter of a muscle fiber is 100 µm. Dystrophin covers only the 
periphery of the myotube/fiber, while MyHC occupies the whole fiber. Therefore, the Dys/MyHC 
ratio between in vivo and in vitro should be around 1/10. 
In order to determine the lower ratio of Dys+ and Dys- cells with a detectable expression of dystrophin, 
we performed co-cultures of Dys+ and Dys- myoblasts at different ratio: 1:1, 1:2 and 1:9 respectively. 
We quantified the production of dystrophin and MyHC as the intensity of western blot bands. Figure 
2I shows a representative western blot. The quantification of western blot bands are reported in figure 
2L (n = 4 independent biological replicates). As expected, the production of dystrophin is directly 
proportional to the number of Dys+ cells in culture. Based on these results, we decided to use the 1:9 
ratio since the dystrophin band is still detectable. 
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3.2 Dystrophin accumulation 
We analyzed dystrophin expression by Dys+ myoblasts and mesoangioblasts, when co-cultured with 
Dys- myoblasts in a 1:9 ratio, through western blot analysis (Fig. 3A). The graph in figure 3B reports 
the percentage of dystrophin restoration versus MyHC intensity. The percentage of dystrophin 
restoration is defined as the intensity of dystrophin from the co-culture normalized by the intensity of 
dystrophin from samples of Dys+ cells (myoblasts or mesoangioblasts, accordingly). Dystrophin 
restoration is represented as a function of MyHC expression because the latter represents the 
differentiation degree of the culture. Since dystrophin expression strictly correlated to the 
differentiation degree of the culture, we observed that, despite the differentiation timing was kept 
constant (8 days), cultures reached different levels of differentiation, in particular for Dys- myoblasts. 
Therefore, in order to compare different samples, dystrophin restoration is reported in function of 
MyHC expression. The results showed that dystrophin restoration is always higher within 
mesoangioblasts co-cultures than myoblasts co-cultures (Fig. 3B, n = 3 independent biological 
replicates for each cell type).  
3.3 Dystrophin expression domain on the myotube surface 
In terms of dystrophin localization, immunofluorescence analysis indicated that Dys+ myoblasts, co-
cultured with Dys- myoblasts (at 1:9 ratio), gave rise to myotubes where dystrophin is expressed in 
defined portion of the myotube (Fig. 4A, B). On the contrary, Dys+ mesoangioblasts in the same 
conditions gave rise to myotubes expressing dystrophin for the majority of their length: the protein 
was expressed almost along the entire myotube (Fig. 4C, D). We analyzed the length of the myotube 
in which dystrophin is expressed, that we named dystrophin domain. The distribution of the 
dystrophin domain length is depicted in figure 4E (n = 3 (Mbs) and n = 2 (Mabs) independent 
biological replicates). The dystrophin restoration domain sustained by myoblasts had an average 
length of 40-100 µm, while mesoangioblasts nuclei contributed to restore dystrophin for 210-240 µm.  
It is worth to underline that we analyzed the number of nuclei per myotube in the dystrophin domain 
intervals, in order to avoid that a longer dystrophin domain could be due to a higher number of nuclei 
per myotube (Fig. 1S). We observed that the average number of nuclei per myotube was comparable 
in myoblasts and mesoangioblasts co-cultures. 
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Discussion  
This study shows that human mesoangioblasts, derived from skeletal muscle vasculature, restore 
dystrophin expression and distribution in an in vitro model of human DMD skeletal muscle tissue-
on-chip. Unexpectedly they do so more efficiently than human skeletal myoblasts. 
The human skeletal muscle tissue-on-chip used in this work is a versatile tool for studying human 
skeletal muscle differentiation in vitro. Recently, we demonstrated that human wild type and DMD 
myoblasts can differentiate optimally in this model thanks to the mechanical and topological stimuli 
exerted20,21. In addition, dystrophin is expressed at significant levels and can be detected by 
immunofluorescence analysis20. These two main characteristics make this model suitable for studying 
human skeletal muscle differentiation in vitro. In this work, the developed human skeletal muscle 
tissue-on-chip have been exploited for studying the ability of  mesoangioblasts from skeletal muscle 
vasculature, in restoring dystrophin expression in hybrid myotubes formed with an excess of 
dystrophic myoblasts and this has been compared with satellite cell-derived myoblasts.  
First, we verified that mesoangioblasts differentiate optimally in our micro-engineered model (Fig. 
2). We observed that the substrate stiffness (15 kPa) and topology (parallel lanes) induced the 
differentiation of mesoangioblasts to functional myotubes (sarcomeric striation of MyHC) expressing 
dystrophin. Indeed the culture in our tissue-on-chip induced a higher expression of dystrophin if 
compared to the standard culture on dish: the ratio between dystrophin and MyHC is higher in the 
culture performed in our microengineered model than the one performed onto standard multiwell 
(Fig. 2H).Our model on chip also offers the additional advantage of an order topology of myotubes. 
In our model, myotubes grow only onto the micro-patterned area and are all oriented along the main 
direction of the patterning. Such spatial organization allows easy quantification of the dystrophin 
expression domain, which would be much more difficult in a standard culture of myotubes, where 
they are randomly oriented. 
Human mesoangioblasts9,13 are a promising cell source for DMD therapy because they overcome 
some of the limitations associated with myoblast intra-muscular injections8. In particular they can be 
delivered through intra-arterial injections since they cross the endothelium and migrate extensively 
in the interstitial space, show long-term survival and partially restore muscle structure and function 
in dystrophic mice and dogs11,12, beside contributing to the muscle satellite cell pool8. Here we tested 
the ability of mesoangioblasts to restore dystrophin expression, in terms of protein accumulation and 
distribution along the surface of myotubes derived from DMD patients, using a micro-engineered 
DMD model.  
Interesting, three different batches of mesoangioblasts showed the ability to restore a significant level 
of dystrophin, which was analyzed by immunofluorescence and western blot. In terms of dystrophin 
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accumulation, restoration of dystrophin by mesoangioblasts was higher than the hypothetic 30% of 
control (according to study on animal or patient with XLDC)7,8, provided that a 1:9 ratio was achieved 
in vitro. The domain of dystrophin restoration due to healthy mesoangioblasts nuclei spanned almost 
along the entire myotube (with an average domain length of 240 µm).  
It is worth to underline that the mesoangioblasts used in this study were used in a phase I/II clinical 
trial based on intra-arterial delivery of mesoangioblasts, in children affected by Duchene Muscular 
Dystrophy at the San Raffaele Hospital in Milan (EudraCT no. 2011-000176-33). Cell delivery in 
vivo is a complex process and reproducing in vitro all the phases (such as delivery, migration, fusion 
to host tissue) will be very challenging. However, these phases may be dissected in separate steps, 
for each of which an in vitro assay may be developed as a predictive tool of the corresponding in vivo 
performance. For example, Boiden chambers coated with endothelium, under various experimental 
conditions, may mimic crossing of the blood vessel in vivo23.  
However, how a mesoangioblast nucleus (or of other myogenic progenitors) contributes to dystrophin 
synthesis and consequently, which is the minimal ratio of delivered/survived and fused cells versus 
resident myofiber nuclei needed to rise dystrophin level above the 30% threshold, is a fundamental 
question in this context. Indeed, in any cell therapy protocol, the preparation of donor cells to be 
injected require their manipulation ex vivo and it is widely known how this step could be crucial for 
the obtainment of good results. In this scenario, we hypothesize that our microscaled in vitro model 
could be used as a quality control test of donor cell batches and could help the prediction of the 
clinical outcomes. In this respect it is interesting to note that preliminary results from the trial14 
indicated that, on the patient with highest engraftment, donor dystrophin (detected by Western Blot 
was) was expressed, albeit at a very low level, when donor DNA (analyzed by satellite micro-
chimerism) was approximately 1% of total DNA in the biopsy.	
Another important aspect to consider is the very large number of variables that may be tested to 
enhance the efficacy of cell therapy, such as for example, pre-treatment of donor cells and/or of host 
muscle cells with molecules that may enhance differentiation, protein synthesis or fusion. Obviously 
it would be impossible to test all these variables in patients and pre-clinical experimental studies on 
animal models may not reveal subtle differences between mouse and human cells24,25. Our model 
could be used as an in vitro standard for testing the extent of dystrophin restoration in parallel to pre-
clinical and before clinical studies. 
In conclusion, we demonstrate that the evaluation of a fundamental clinical outcome such as 
dystrophin expression, conducted on skeletal muscle-on-chip could be a valuable support during pre-
clinical phases or clinical trials. 
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Figure captions 
Figure 1: Description of the experimental strategy. Clinical trial (light red box) on stem cell therapies 
are based on the isolation and expansion of stem cells from a healthy donor following GMP 
guidelines. These cells are then injected into the DMD patient. Clinical trial on chip (light blue box) 
is based on the exploitation of the skeletal muscle on a chip, which allow to perform multiparametric 
and highthroughput experiments in vitro. Dys+ and Dys- cells are co-cultured at different ratio within 
the skeletal muscle on chip. The proportion used for the core set of experiments was 1 Dys+ and 9 
Dys- cells (1:9). Dys+ and Dys- cells fuse and result in myotubes composed of Dys+ and Dys- nuclei. 
The micro-engineered model induces the functional maturation of the myotubes, promoting MyHC 
sarcomeric organization and dystrophin expression within 8 days. The co-cultures are analyzed in 
terms of dystrophin accumulation and localization within the membrane. The knowledge acquired is 
then integrated within the clinical trial process. 
Figure 2: Validation of the assay. We verified the differentiation of primary myoblasts and 
mesoangioblasts on our device and characterized the co-culture assay.  A-F: functional maturation of 
human myoblasts (A, C) human mesoangioblasts (B, D) and human DMD primary myoblasts (E,F) 
was confirmed through immunofluorescence against MyHC (A, B, E) and Dystrophin (C, D, F). G: 
Graph representing the percentage of myotubes derived from Dys- cells (green), Dys+ cells (red), not 
marked cells (white), and Dys- cells fused with Dys+ cells (orange). H: Graph representing the ratio 
between the band intensity of dystrophin and MyHC in Dys+ myoblasts (Mbs) and 
Dys+mesoangioblasts (Mabs). The culture were performed in standard 48 multiwell (MW) and onto 
the micro-engineered skeletal muscle chip (HY). I: a representative western blot of the co-culture of 
myoblasts. Samples: 1:1, 1:2, 1:9 are the ratio of Dys+ and Dys- myoblasts, DMD are Dys- primary 
myoblasts (affected by DMD), H are Dys+ myoblasts (from healthy donor). J: quantification of the 
bands intensity. Error bars, s.d.; n = 3 (E) and n = 4 (G) independent biological replicates. *: p-value 
< 0.05; **: p-value < 0.01 (two-sided t-test).  
Figure 3: Analysis of the accumulation of dystrophin within co-culture experiments. A: representative 
western blot of the co-culture experiments of Dys+ and Dys- myoblasts (Mbs) and Dys+ 
mesoangioblasts (Mabs) and Dys- myoblasts. H = sample with only Dys+ cells (Mbs or Mabs); DYS 
= dystrophin, MyHC = myosin heavy chain; β-ACT = β-actinin B: quantification of the percentage 
of dystrophin restoration as function of MyHC expression. Error bars, s.d.; n = 3 independent 
biological replicates.  
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Figure 4: Analysis of the length of dystrophin domain restored in the co-colture experiments. A-D: 
immunofluorescence against dystrophin in the 1:9 co-culture of Dys+ and Dys- myoblasts (A, B) and 
1:9 co-culture of Dys+ mesoangioblasts and Dys- myoblasts (C, D). E: quantification of dystrophin 
domain length. Error bars, s.d.; n = 3 (MYB) and n = 2 (PE) independent biological replicates.  
Figure 1S: cell population (Dys- and Dys+) staining. Representative images of several strategies to 
stain the two cell populations. A: hoechst staining of living myoblasts, we observed reduced cell 
viability after 5 days of culture. B: infection with a GFP adenovirus, which efficiency was low (around 
50%). C: infection with a LacZ lentivirus, which stained the cells with a high efficiency (90%), 
however, the β-galactosidase was translocated to all the nuclei inside the myotube and after 10-12 
days, we observed myotubes with all positive nuclei or with all negative nuclei and only in few cases 
gradient of staining. D-F: staining with lipophilic tracers DiI (red, Dys-) and DiO (green, Dys+), which 
allowed us to visualize and quantify the myotubes formed by Dys- and Dys+ cells. 
 
Figure 2S: nuclei distribution. Quantification of nuclei distribution as function of dystrophin domain 
length. We divided the myotubes based on the domain length of dystrophin expression and counted 
the number of nuclei in each myotube within the same dystrophin domain. Error bars, s.d.; n = 2 
independent biological replicates  
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